Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a ...

Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation ...

adding a third in 2021 when it got FDA clearance for cervical cancer therapy Tivdak (tisotumab vedotin). "As a pioneer and leader in antibody-drug conjugate (ADC) technology, protecting our ...

Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The ...

2359.HK WuXi AppTec Co., Ltd.